The aim of our study was to develop CD38-specific nanobody-based BARs specific for three distinct, non-overlapping epitopes on CD38 and to evaluate their potential to induce lysis of myeloma cells in vitro and ex vivo. This evidence concerns the gene CD38 and plasma cell myeloma.